Grünenthal strengthens its Genetic Medicine Capabilities and joins the Cluster for Nucleic Acid Therapeutics Munich
2 Articles
2 Articles
Grünenthal strengthens its Genetic Medicine Capabilities and joins the Cluster for Nucleic Acid Therapeutics Munich
AACHEN, Germany, July 16, 2026 /PRNewswire/ -- Grünenthal announced today that the company has joined the Cluster for Nucleic Acid Therapeutics Munich (CNATM), a Munich-centred innovation network that brings together leading universities, research institutions, biotech companies and industry partners to…
Grünenthal Enhances Genetic Medicine Expertise by Joining the Munich Cluster for Nucleic Acid Therapeutics
Grünenthal Joins Munich-based Cluster for Nucleic Acid Therapeutics Aachen, Germany – Grünenthal, a global leader in pain management and related diseases, announced today its official partnership with the Cluster for Nucleic Acid Therapeutics Munich (CNATM) on Thursday, July 16, 2026. This collaboration will bring together leading universities, research institutions, biotech companies... Source
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
